Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.76 |
| ▸ | ESR1 | P03372 | 8/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 3/20 | 0.42 |
| ▸ | DRD5 | P21918 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128209 | 0.86 | ESR2 (1.00) | ESR2ESR1LMNAMAPK1ALDH1A1 | |
| SCHEMBL5129674 | 0.84 | ESR2 (1.00) | ESR2ESR1LMNAMAPK1ALDH1A1 | |
| SCHEMBL5117321 | 0.82 | ESR2 (1.00) | ESR2ESR1LMNAMAPK1ALDH1A1 | |
| SCHEMBL5112889 | 0.81 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL5124213 | 0.79 | ESR2 (1.00) | ESR2ESR1MAPK1 | |
| SCHEMBL14176451 | 0.79 | ESR2 (0.74) | ESR2ESR1 | |
| SCHEMBL14176454 | 0.77 | ESR2 (0.71) | ESR2ESR1 | |
| SCHEMBL5112589 | 0.77 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL1662878 | 0.73 | ESR2 (0.84) | ESR2ESR1 | |
| SCHEMBL5117316 | 0.67 | ESR2 (0.59) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | ESR2, ESRRA, ESRRG | ESR2 1/4885ESR1 9/4885LMNA 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.